What does Cadrenal Therapeutics, Inc. do?
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and…
What is Cadrenal Therapeutics, Inc.'s P/E and P/B ratio?
Cadrenal Therapeutics, Inc. has a P/E ratio of -0.2 and a P/B ratio of 0.85.
What is Cadrenal Therapeutics, Inc.'s debt-to-equity ratio?
Cadrenal Therapeutics, Inc. has a debt-to-equity ratio of 0.00.
How much does Cadrenal Therapeutics, Inc. owe compared with what it owns?
Cadrenal Therapeutics, Inc. owes $0.27 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Cadrenal Therapeutics, Inc.'s Positivity rank?
Cadrenal Therapeutics, Inc. is ranked #858 of 6,774 companies globally and #146 of 4,000 in United States on PositoAI, with a Positivity Score of 23,622.
Does Cadrenal Therapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Cadrenal Therapeutics, Inc..
Where can I read the latest news about Cadrenal Therapeutics, Inc.?
Recent headlines about Cadrenal Therapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Cadrenal Therapeutics, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Cadrenal Therapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.